Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EMN 2021 | Monoclonal antibodies for smoldering or newly diagnosed myeloma

Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, discusses the role of monoclonal antibody therapies in the treatment of patients with smoldering or newly diagnosed multiple myeloma. In particular, Dr Zamagni discusses the use of monoclonal antibodies in the first-line setting in combination with immunomodulatory drugs and proteasome inhibitors. Dr Zamagni also highlights the potential of monoclonal antibodies to delay disease progression in patients with smoldering multiple myeloma. This interview took place during the 2021 European Myeloma Network (EMN) congress.

Disclosures

Elena Zamagni, MD, PhD, has received honoraria from, and participated in advisory boards for Amgen, Sanofi, BMS, Takeda, Janssen, Oncopeptides and Karyopharm.